Skip to main content
ARDX
NASDAQ Life Sciences

Ardelyx Chief Commercial Officer Resigns Effective August 28

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$4.04
Mkt Cap
$1.012B
52W Low
$3.86
52W High
$8.4
52W Position info
4.7% above low
Off High info
52% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ARDX is trading near its 52-week low of $3.86 (4.7% above the low).

Summary

Ardelyx's Chief Commercial Officer Eric Foster resigned effective August 28, 2026, to pursue another opportunity. The departure follows a recent IBSRELA revenue guidance cut.


Key Events · Executive and Board Changes · ARDX

  • Chief Commercial Officer Resigns

    Eric Foster notified Ardelyx on August 11, 2026, of his resignation as Chief Commercial Officer, effective August 28, 2026.

  • Reason for Departure

    Foster resigned to pursue a new opportunity with a pre-commercial company; the filing states the resignation is not due to any disagreement with Ardelyx.

  • Timing After Guidance Cut

    The resignation follows Ardelyx's August 6, 2026 announcement cutting full-year IBSRELA revenue guidance by $60 million due to missed internal expectations.

  • Commercial Leadership Vacancy

    Ardelyx has not announced a successor for the Chief Commercial Officer role, leaving a key commercial position open during a period of revenue uncertainty.


Analysis · ARDX · Life Sciences

Eric Foster, Chief Commercial Officer, resigned to join a pre-commercial company. The departure comes just weeks after Ardelyx cut its full-year IBSRELA revenue guidance by $60 million, raising questions about commercial leadership stability during a critical period for the company's lead product.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARDX was trading at $4.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $3.86 to $8.40. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARDX - Latest Insights

ARDX
Nov 03, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.08
Real-time Price: $3.16 info
Change: +$0.075 (+2%) info
Market Cap: $793.08M info
ARDX
Nov 03, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.04
Real-time Price: $3.16 info
Change: +$0.1142 (+4%) info
Market Cap: $793.08M info
ARDX
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.05
Real-time Price: $3.16 info
Change: +$0.105 (+3%) info
Market Cap: $793.08M info
ARDX
Aug 06, 2026, 4:49 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.08
Real-time Price: $3.16 info
Change: -$0.925 (-23%) info
Market Cap: $793.08M info
ARDX
Aug 06, 2026, 4:12 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.50
Real-time Price: $3.16 info
Change: -$1.35 (-30%) info
Market Cap: $793.08M info